A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AM...
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
About this item
Full title
Author / Creator
Garcia-Manero, G , Sekeres, M A , Egyed, M , Breccia, M , Graux, C , Cavenagh, J D , Salman, H , Illes, A , Fenaux, P , DeAngelo, D J , Stauder, R , Yee, K , Zhu, N , Lee, J-H , Valcarcel, D , MacWhannell, A , Borbenyi, Z , Gazi, L , Acharyya, S , Ide, S , Marker, M and Ottmann, O G
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is <2 years, novel agents are needed to improve outcomes. This phase 1b/2b trial (
n
=113) was designed to determine the maximum tolerat...
Alternative Titles
Full title
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5729337
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5729337
Other Identifiers
ISSN
0887-6924
E-ISSN
1476-5551
DOI
10.1038/leu.2017.159
